Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cenicriviroc (Primary) ; Tropifexor (Primary)
  • Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
  • Focus Adverse reactions
  • Acronyms TANDEM; TANDEM NASH
  • Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals

    • Most Recent Events

    • 14 Nov 2023 Results from NCT03517540, NCT03912532 deriving baseline/screening biopsies evaluating the utility of the HistoIndex artificial intelligence (AI) digital pathology tool to improve the reliability of fibrosis staging in NASH, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
    • 14 Nov 2023 Results from the Tandem study analyzing reduction screen failure rates using ballooning and fibrosis assessment with second harmonic generation/Two-Photon excitation microscopy and artificial intelligence analysis, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
    • 11 May 2023 Results assessing safety and efficacy of TXR and CVC combination, compared with respective monotherapies published in the Hepatology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top